Vaccines against malaria

Philosophical Transactions of the Royal Society B: Biological Sciences

Volumn 366, Issue 1579, 2011, Pages 2806-2814

  Hill, Adrian V S ^a  

^a UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

Malaria; Parasite; Vaccines

Indexed keywords

BLOOD; CAUSE OF DEATH; COST-BENEFIT ANALYSIS; DISEASE TRANSMISSION; DISEASE TREATMENT; DRUG DEVELOPMENT; IMMUNITY; INFECTIOUS DISEASE; LIFE CYCLE; MALARIA; NUMERICAL MODEL; PROTEIN; PUBLIC HEALTH; VACCINATION; VACCINE;

PLASMODIUM FALCIPARUM;

EID: 80052433273     PISSN: 09628436     EISSN: 14712970     Source Type: Journal    
DOI: 10.1098/rstb.2011.0091     Document Type: Review

References (62)

1. Russell, P. F. & Mohan, B. N. 1942 The immunization of fowls against mosquito-borne Plasmodium gallinaceum by injections of serum and of inactivated homologous sporozoites. J. Exp. Med. 76, 477-495. (doi:10.1084/jem.76. 5.477)
2. Freund, J., Sommer, H. E. & Walter, A. W. 1945 Immunization against malaria: vaccination of ducks with killed parasites incorporated with adjuvants. Science 102, 200-202. (doi:10.1126/science.102.2643.200)
3. Knox, D. P. & Redmond, D. L. 2006 Parasite vaccines - recent progress and problems associated with their development. Parasitology 133(Suppl.), S1-S8.
4. Meeusen, E. N., Walker, J., Peters, A., Pastoret, P. P. & Jungersen, G. 2007 Current status of veterinary vaccines. Clin. Microbiol. Rev. 20, 489-510 (doi:10.1128/CMR. 00005-07)
5. World Health Organization 2010 Global malaria programme 2010. Geneva, Switzerland: WHO. See http://www.who.int/malaria/publications/atoz/9789241564106/en/index.html.
6. Hoffman, S. L. et al. 2010 Development of a metabolically active, non-replicating sporozoite vaccine to prevent Plasmodium falciparum malaria. Hum. Vaccine 6, 97-106 (doi:10.4161/hv.6.1.10396)
7. Anders, R. F., Adda, C. G., Foley, M. & Norton, R. S. 2010 Recombinant protein vaccines against the asexual blood stages of Plasmodium falciparum. Hum. Vaccine 6, 39-53 (doi:10.4161/hv.6.1.10712)
8. Lightowlers, M. W. 2010 Eradication of Taenia solium cysticercosis: a role for vaccination of pigs. Int. J. Parasitol. 40, 1183-1192 (doi:10.1016/j.ijpara.2010.05.001)
9. Marsh, K. & Kinyanjui, S. 2006 Immune effector mechanisms in malaria. Parasite Immunol. 28, 51-60 (doi:10. 1111/j.1365-3024.2006.00808.x)
10. Nussenzweig, R. S., Vanderberg, J., Most, H. & Orton, C. 1967 Protective immunity produced by the injection of x-irradiated sporozoites of Plasmodium berghei. Nature 216, 160-162 (doi:10.1038/216160a0)
11. Doolan, D. L. & Hoffman, S. L. 1997 Pre-erythrocyticstage immune effector mechanisms in Plasmodium spp. infections. Phil. Trans. R. Soc. Lond. B 352, 1361-1367 (doi:10.1098/rstb.1997.0121)
12. Clyde, D. F. 1975 Immunization of man against falciparum and vivax malaria by use of attenuated sporozoites. Am. J. Trop. Med. Hyg. 24, 397-401.
13. Anonymous 1982 Malaria vaccine is near. New York Times, 3 August 1982.
14. Ballou, W. R. et al. 1987 Safety and efficacy of a recombinant DNA Plasmodium falciparum sporozoite vaccine. Lancet 1, 1277-1281 (doi:10.1016/S0140-6736(87)90540-X)
15. Patarroyo, M. E. et al. 1988 A synthetic vaccine protects humans against challenge with asexual blood stages of Plasmodium falciparum malaria. Nature 332, 158-161 (doi:10.1038/332158a0)
16. Stoute, J. A. et al. 1997 A preliminary evaluation of a recombinant circumsporozoite protein vaccine against Plasmodium falciparum malaria. RTS,S Malaria Vaccine Evaluation Group. N. Engl. J. Med. 336, 86-91 (doi:10.1056/NEJM199701093360202)
17. Bojang, K. A. et al. 2001 Efficacy of RTS,S/AS02 malaria vaccine against Plasmodium falciparum infection in semi-immune adult men in The Gambia: a randomised trial. Lancet 358, 1927-1934 (doi:10.1016/S0140- 6736(01)06957-4)
18. Schofield, L., Villaquiran, J., Ferreira, A., Schellekens, H., Nussenzweig, R. & Nussenzweig, V. 1987 Gamma interferon, CD8{thorn} T cells and antibodies required for ismmunity to malaria sporozoites. Nature 330, 664-666 (doi:10.1038/330664a0)
19. Wang, R. et al. 1998 Induction of antigen-specific cytotoxic T lymphocytes in humans by a malaria DNA vaccine. Science 282, 476-480 (doi:10.1126/science.282.5388.476)
20. McConkey, S. J. et al. 2003 Enhanced T-cell immunogenicity of plasmid DNA vaccines boosted by recombinant modified vaccinia Ankara in humans. Nat. Med. 9, 729-735 (doi:10.1038/nm881)
21. Ballou, W. R. & Cahill, C. P. 2007 Two decades of commitment to malaria vaccine development: GlaxoSmith Kline Biologicals. Am. J. Trop. Med. Hyg. 77, 289-295.
22. The malERA Consultative Group on Vaccines 2011 A research agenda for malaria eradication: vaccines. PLoS Med 8, e1000398 (doi:10.1371/journal.pmed. 1000398)
23. Moorthy, V. S. et al. 2009 Report of a consultation on the optimization of clinical challenge trials for evaluation of candidate blood stage malaria vaccines, 18-19 March 2009, Bethesda, MD, USA. Vaccine 27, 5719-5725 (doi:10.1016/j.vaccine.2009.07.049)
24. Kester, K. E. et al. 2009 Randomized, double-blind, phase 2a trial of falciparum malaria vaccines RTS,S/ AS01B and RTS,S/AS02A in malaria-naive adults: safety, efficacy, and immunologic associates of protection. J. Infect. Dis. 200, 337-346 (doi:10.1086/600120)
25. Bejon, P., Andrews, L., Andersen, R. F., Dunachie, S., Webster, D., Walther, M., Gilbert, S. C., Peto, T. & Hill, A. V. S. 2005 Calculation of liver-to-blood inocula, parasite growth rates, and preerythrocytic vaccine efficacy, from serial quantitative polymerase chain reaction studies of volunteers challenged with malaria sporozoites. J. Infect. Dis. 191, 619-626 (doi:10.1086/427243)
26. Moorthy, V. S. & Ballou, W. R. 2009 Immunological mechanisms underlying protection mediated by RTS,S: a review of the available data. Malar. J. 8, 312 (doi:10. 1186/1475-2875-8-312)
27. Olotu, A. I., Fegan, G. & Bejon, P. 2010 Further analysis of correlates of protection from a phase 2a trial of the falciparum malaria vaccines RTS,S/AS01B and RTS,S/ AS02A in malaria-naive adults. J. Infect. Dis. 201, 970-971 (doi:10.1086/651025)
28. Aide, P. et al. 2010 Safety, immunogenicity and duration of protection of the RTS,S/AS02(D) malaria vaccine: one year follow-up of a randomized controlled phase I/ IIb trial. PLoS ONE 5, e13838 (doi:10.1371/journal. pone.0013838)
29. Guinovart, C. et al. 2009 Insights into long-lasting protection induced by RTS,S/AS02A malaria vaccine: further results from a phase IIb trial in Mozambican children. PLoS ONE 4, e5165 (doi:10.1371/journal.pone. 0005165)
30. Bejon, P. et al. 2008 Efficacy of RTS,S/AS01E vaccine against malaria in children 5 to 17 months of age. N. Engl. J. Med. 359, 2521-2532 (doi:10.1056/NEJMoa0807381)
31. Olotu, A. et al. 2011 Efficacy of RTS,S/AS01E malaria vaccine and exploratory analysis on anti-circumsporozoite antibody titres and protection in children aged 5-17 months in Kenya and Tanzania: a randomised controlled trial. Lancet Infect. Dis. 11, 102-109 (doi:10. 1016/S1473-3099(10)70262-0)
32. Stoute, J. A. et al. 1998 Long-term efficacy and immune responses following immunization with the RTS,S malaria vaccine. J. Infect. Dis. 178, 1139-1144 (doi:10.1086/515657)
33. Hoffman, S. L. et al. 2002 Protection of humans against malaria by immunization with radiation-attenuated Plasmodium falciparum sporozoites. J. Infect. Dis. 185, 1155-1164 (doi:10.1086/339409)
34. Vaughan, A. M., Wang, R. & Kappe, S. H. 2010 Genetically engineered, attenuated whole-cell vaccine approaches for malaria. Hum. Vaccine 6, 107-113 (doi:10.4161/hv.6.1.9654)
35. Roestenberg, M. et al. 2009 Protection against a malaria challenge by sporozoite inoculation. N. Engl. J. Med. 361, 468-477 (doi:10.1056/NEJMoa0805832)
36. McCarthy, J. S. & Good, M. F. 2010 Whole parasite blood stage malaria vaccines: a convergence of evidence. Hum. Vaccine 6, 114-123 (doi:10.4161/hv.6.1.10394)
37. Pombo, D. J. et al. 2002 Immunity to malaria after administration of ultra-low doses of red cells infected with Plasmodium falciparum. Lancet 360, 610-617 (doi:10.1016/S0140-6736(02)09784-2)
38. Hill, A. V. et al. 2010 Prime-boost vectored malaria vaccines: progress and prospects. Hum. Vaccine 6, 78-83. (doi:10.4161/hv.6.1.10116)
39. Bruder, J. T., Angov, E., Limbach, K. J. & Richie, T. L. 2010 Molecular vaccines for malaria. Hum. Vaccine 6, 54-77. (doi:10.4161/hv.6.1.10463)
40. Schmidt, N. W., Butler, N. S., Badovinac, V. P. & Harty, J. T. 2010 Extreme CD8 T cell requirements for antimalarial liver-stage immunity following immunization with radiation attenuated sporozoites. PLoS Pathog. 6, e1000998. (doi:10.1371/journal.ppat.1000998)
41. Reyes-Sandoval, A., Berthoud, T., Alder, N., Siani, L., Gilbert, S. C., Nicosia, A., Colloca, S., Cortese, R. & Hill, A. V. S. 2010 Prime-boost immunization with adenoviral and modified vaccinia virus Ankara vectors enhances the durability and polyfunctionality of protective malaria CD8{thorn} T-cell responses. Infect. Immun. 78, 145-153. (doi:10.1128/IAI.00740-09)
42. Capone, S. et al. 2010 Immune responses against a liverstage malaria antigen induced by simian adenoviral vector AdCh63 and MVA prime-boost immunisation in non-human primates. Vaccine 29, 256-265. (doi:10. 1016/j.vaccine.2010.10.041)
43. Reyes-Sandoval, A., Wyllie, D. H., Bauza, K., Milicic, A., Forbes, E. K., Rollier, C. S. & Hill, A. V. S. In press. CD8{thorn} T effector memory cells protect against liver-stage malaria. J. Immunol.
44. + T cell immunity to human malaria induced by chimpanzee adenovirus-MVA immunization.
45. Bakshi, S. & Imoukhuede, E. B. 2010 Malaria Vectored Vaccines Consortium (MVVC). Hum. Vaccine 6, 433-434. (doi:10.4161/hv.6.6.12543)
46. Radosevic, K., Rodriguez, A., Lemckert, A. A. C., van der Meer, M., Gillissen, G., Warnar, C., von Eyben, R., Pau, M. G. & Goudsmit, J. 2010 The Th1 immune response to Plasmodium falciparum circumsporozoite protein is boosted by adenovirus vectors 35 and 26with a homologous insert. Clin. Vaccine Immunol. 17, 1687-1694 (doi:10.1128/CVI.00311-10)
47. Goodman, A. L. & Draper, S. J. 2010 Blood-stage malaria vaccines-recent progress and future challenges. Ann. Trop. Med. Parasitol. 104, 189-211. (doi:10.1179/ 136485910X12647085215534)
48. Ellis, R. D. et al. 2009 A Phase 1 study of the blood-stage malaria vaccine candidate AMA1-C1/Alhydrogel with CPG 7909, using two different formulations and dosing intervals. Vaccine 27, 4104-4109. (doi:10.1016/j.vaccine.2009.04.077)
49. Druilhe, P. et al. 2005 A malaria vaccine that elicits in humans antibodies able to kill Plasmodium falciparum. PLoS Med. 2, e344. (doi:10.1371/journal.pmed.0020344)
50. Takala, S. L. et al. 2009 Extreme polymorphism in a vaccine antigen and risk of clinical malaria: implications for vaccine development. Sci. Transl. Med. 1, 2ra5. (doi:10. 1126/scitranslmed.3000257)
51. Genton, B. et al. 2002 A recombinant blood-stage malaria vaccine reduces Plasmodium falciparum density and exerts selective pressure on parasite populations in a phase 1-2b trial in Papua New Guinea. J. Infect. Dis. 185, 820-827. (doi:10.1086/339342)
52. Spring, M. D. et al. 2009 Phase 1/2a study of the malaria vaccine candidate apical membrane antigen-1 (AMA-1) administered in adjuvant system AS01B or AS02A. PLoS ONE 4, e5254. (doi:10.1371/journal.pone.0005254)
53. Thompson, F. M. et al. 2008 Evidence of blood stage efficacy with a virosomal malaria vaccine in a Phase IIa clinical trial. PLoS ONE 3, e1493. (doi:10.1371/journal. pone.0001493)
54. Carter, R. & Chen, D. H. 1976 Malaria transmission blocked by immunisation with gametes of the malaria parasite. Nature 263, 57-60. (doi:10.1038/263057a0)
55. Ramjanee, S. et al. 2007 The use of transgenic Plasmodium berghei expressing the Plasmodium vivax antigen P25 to determine the transmission-blocking activity of sera from malaria vaccine trials. Vaccine 25, 886-894. (doi:10.1016/j.vaccine.2006.09.035)
56. Wu, Y. et al. 2008 Phase 1 trial of malaria transmission blocking vaccine candidates Pfs25 and Pvs25 formulated with montanide ISA 51. PLoS ONE 3, e2636. (doi:10. 1371/journal.pone.0002636)
57. Dinglasan, R. R., Kalume, D. E., Kanzok, S. M., Ghosh, A. K., Muratova, O., Pandey, A. & Jacobs-Lorena, M. 2007 Disruption of Plasmodium falciparum development by antibodies against a conserved mosquito midgut antigen. Proc. Natl Acad. Sci. USA 104, 13 461-13 466. (doi:10.1073/pnas.0702239104)
58. Ockenhouse, C. F. et al. 1998 Phase I/IIa safety, immunogenicity, and efficacy trial of NYVAC-Pf7, a poxvectored, multiantigen, multistage vaccine candidate for Plasmodium falciparum malaria. J. Infect. Dis. 177, 1664-1673. (doi:10.1086/515331)
59. Prieur, E., Gilbert, S. C., Schneider, J., Moore, A. C., Sheu, E. G., Goonetilleke, N., Robson, K. J. H. & Hill, A. V. A. 2004 A Plasmodium falciparum candidate vaccine based on a six-antigen polyprotein encoded by recombinant poxviruses. Proc. Natl Acad. Sci. USA 101, 290-295. (doi:10.1073/pnas.0307158101)
60. Hutchings, C. L., Birkett, A. J., Moore, A. C. & Hill, A. V. 2007 Combination of protein and viral vaccines induces potent cellular and humoral immune responses and enhanced protection from murine malaria challenge. Infect. Immun. 75, 5819-5826. (doi:10.1128/IAI.00828-07)
61. Malaria Vaccine Technology Roadmap 2006 Executive summary. See http://www.malariavaccine.org/files/Malaria_Vaccine_TRM_Final_000.pdf.
62. Arevalo-Herrera, M., Chitnis, C. & Herrera, S. 2010 Current status of Plasmodium vivax vaccine. Hum. Vaccine 6, 124-132. (doi:10.4161/hv.6.1.9931)